Literature DB >> 20349410

Myocardial scintigraphy and clinical stratification as predictors of events in renal transplant candidates.

Rodolfo L Arantes1, Luis Henrique W Gowdak, Flavio J de Paula, Luis Estevan Ianhez, Jose Antonio F Ramires, Eduardo M Krieger, José Jayme G De Lima.   

Abstract

BACKGROUND: We tested the hypothesis that the universal application of myocardial scanning with single-photon emission computed tomography (SPECT) would result in better risk stratification in renal transplant candidates (RTC) compared with SPECT being restricted to patients who, in addition to renal disease, had other clinical risk factors.
METHODS: RTCs (n=363) underwent SPECT and clinical risk stratification according to the American Society of Transplantation (AST) algorithm and were followed up until a major adverse cardiovascular event (MACE) or death.
RESULTS: Of the 363 patients, 79 patients (22%) had an abnormal SPECT scan and 270 (74%) were classified as high risk. Both methods correctly identified patients with increased probability of MACE. However, clinical stratification performed better (sensitivity and negative predictive value 99% and 99% vs. 25% and 87%, respectively). High-risk patients with an abnormal SPECT scan had a modest increased risk of events (log-rank = 0.03; hazard ratio [HR] = 1.37; 95% confidence interval [95% CI], 1.02-1.82). Eighty-six patients underwent coronary angiography, and coronary artery disease (CAD) was found in 60%. High-risk patients with CAD had an increased incidence of events (log-rank = 0.008; HR=3.85; 95% CI, 1.46-13.22), but in those with an abnormal SPECT scan, the incidence of events was not influenced by CAD (log-rank = 0.23). Forty-six patients died. Clinical stratification, but not SPECT, correlated with the probability of death (log-rank = 0.02; HR=3.25; 95% CI, 1.31-10.82).
CONCLUSION: SPECT should be restricted to high-risk patients. Moreover, in contrast to SPECT, the AST algorithm was also useful for predicting death by any cause in RTCs and for selecting patients for invasive coronary testing.

Entities:  

Mesh:

Year:  2010        PMID: 20349410

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  3 in total

Review 1.  Cardiac testing for coronary artery disease in potential kidney transplant recipients.

Authors:  Louis W Wang; Magid A Fahim; Andrew Hayen; Ruth L Mitchell; Laura Baines; Stephen Lord; Jonathan C Craig; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

2.  Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial.

Authors:  Charles A Herzog; Mengistu A Simegn; Yifan Xu; Salvatore P Costa; Roy O Mathew; Mohammad C El-Hajjar; Sanjeev Gulati; Rafael A Maldonado; Eric Daugas; Magdelena Madero; Jerome L Fleg; Rebecca Anthopolos; Gregg W Stone; Mandeep S Sidhu; David J Maron; Judith S Hochman; Sripal Bangalore
Journal:  J Am Coll Cardiol       Date:  2021-05-11       Impact factor: 27.203

3.  Diagnosis and treatment of coronary artery disease in hemodialysis patients evaluated for transplant.

Authors:  Jose Jg De Lima; Luis Henrique W Gowdak; Flavio J de Paula
Journal:  Transplant Res       Date:  2012-04-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.